Correlation between Genetic Markers and Contrast-enhanced CT Texture Analysis in Colon Cancer

Nora Jensen^*
*Correspondence: Nora Jensen, Department of Molecular and Structural Physiology, University of Copenhagen, København, Denmark, Email:

Introduction

The field of medical imaging has witnessed remarkable advancements in recent decades, particularly in the realm of cancer diagnosis and treatment. Colon cancer, a significant contributor to cancer-related morbidity and mortality globally, has been a focus of extensive research aimed at improving early detection and prognostication. One promising area of investigation is the correlation between genetic markers and contrast-enhanced CT texture analysis, which holds potential for enhancing diagnostic accuracy and personalized treatment strategies in colon cancer patients [1].

Colon cancer is a complex disease characterized by genetic alterations that drive tumorigenesis and progression. Key genetic markers implicated in colon cancer include mutations in the APC gene, KRAS, BRAF, and TP53, among others. These genetic abnormalities not only contribute to tumor initiation but also influence disease aggressiveness, treatment response, and patient outcomes. As research continues to unravel the complexities of tumor biology, leveraging these synergies will be instrumental in optimizing patient care and advancing precision oncology. In conclusion, the correlation between genetic markers and contrast-enhanced CT texture analysis holds immense promise for improving outcomes in colon cancer patients [2].

Description

Contrast-enhanced Computed Tomography (CT) imaging is a cornerstone in the diagnosis and staging of colon cancer. It provides detailed anatomical information and enables the assessment of tumor size, extent, and involvement of adjacent structures. Moreover, advancements in CT technology, such as Multidetector CT (MDCT) and perfusion CT, have further refined imaging protocols, allowing for more accurate tumor characterization and evaluation of vascular parameters. Texture Analysis (TA) is a quantitative imaging technique that evaluates the spatial arrangement and distribution of voxel intensities within a Region of Interest (ROI) on medical images. In the context of contrast-enhanced CT, texture analysis can extract valuable information regarding tumor heterogeneity, microenvironmental characteristics, and angiogenic patterns. By analyzing texture features such as entropy, homogeneity, and skewness, CT texture analysis aims to uncover subtle variations within tumors that may be indicative of underlying genetic alterations or prognostic significance [3].

Several studies have explored the correlation between genetic markers and contrast-enhanced CT texture analysis in colon cancer. These investigations often involve retrospective analyses of imaging data and molecular profiling from patient cohorts. The overarching goal is to identify imaging biomarkers or radiogenomic signatures that mirror underlying genetic events and provide clinically relevant insights. Studies have suggested associations between specific APC gene mutations and distinct CT texture patterns in colon tumors. For instance, loss-of-function mutations in APC may be linked to increased tumor vascularity or heterogeneous enhancement patterns on CT imaging [4].

The presence of KRAS mutations, particularly in exon 2, has been correlated with specific texture features indicative of tumor aggressiveness or resistance to targeted therapies. Similarly, BRAF V600E mutations have been associated with altered CT texture parameters, potentially reflecting differences in tumor biology and treatment response. Microsatellite Instability (MSI)-high status, a marker of DNA mismatch repair deficiency, has been studied in relation to CT texture analysis. High MSI has been associated with unique texture signatures on CT, which may have implications for immunotherapy response and patient stratification. These correlation studies underscore the intricate interplay between genetic drivers of colon cancer and radiomic features derived from contrast-enhanced CT imaging. By leveraging advanced analytical techniques and machine learning algorithms, researchers aim to elucidate predictive models that integrate genetic and imaging data for improved patient management [5].

Conclusion

In conclusion, the correlation between genetic markers and contrast-enhanced CT texture analysis represents a burgeoning field with significant implications for the management of colon cancer. Integrating molecular insights with radiomic phenotypes holds promise for refining risk stratification, guiding treatment decisions, and monitoring therapeutic response. Future directions in this area involve large-scale prospective studies, validation of radiogenomic models, and integration into clinical practice to realize the full potential of precision medicine in colon cancer care. The correlation between genetic markers and contrast-enhanced CT texture analysis represents a paradigm shift in the field of colon cancer management. Integrating molecular information with advanced imaging techniques not only enhances diagnostic accuracy but also enables personalized treatment strategies. By harnessing the power of multidisciplinary approaches, we can unravel the intricacies of tumor behavior, identify novel therapeutic targets, and ultimately pave the way towards more effective cancer management. This symbiotic relationship between genetics and imaging underscores the transformative potential of precision medicine in combating colon cancer and other malignancies.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Sung, Hyuna, Jacques Ferlay, Rebecca L. Siegel and Mathieu Laversanne, et al. "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries." CA: Cancer J Clinici 71 (2021): 209-249.

Google Scholar, Crossref, Indexed at

2. Rawla, Prashanth, Tagore Sunkara and Adam Barsouk. "Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors." Gastroenterol Rev/Prz Gastroenterol 14 (2019): 89-103.

Google Scholar, Crossref, Indexed at

3. Taguchi, Narumi, Seitaro Oda, Yasuhiro Yokota and Sadahiro Yamamura, et al. "CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach." Euro J Radiol 118 (2019): 38-43.

Google Scholar, Crossref, Indexed at

4. Lubner, Meghan G., Andrew D. Smith, Kumar Sandrasegaran and Dushyant V. Sahani, et al. "CT texture analysis: Definitions, applications, biologic correlates, and challenges." Radiographic 37 (2017): 1483-1503.

Google Scholar, Crossref, Indexed at

5. Nioche, Christophe, Fanny Orlhac, Sarah Boughdad and Sylvain Reuzé, et al. "LIFEx: A freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity." Cancer Res 78 (2018): 4786-4789.

Google Scholar, Crossref, Indexed at